Optimal dose of etanercept in the treatment of rheumatoid arthritis
Elizabeth Mary Curtis, Jonathan Lewis MarksDepartment of Rheumatology, University Hospital Southampton, Southampton, Hampshire, UKAbstract: Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy...
Saved in:
Main Authors: | Curtis EM, Marks JL |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/d11f11d8cc3d4f50ad7576ab43040d03 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
by: Michihito Sato, et al.
Published: (2011) -
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
by: Franz Thiele, et al.
Published: (2021) -
Certolizumab in the long-term treatment of rheumatoid arthritis
by: Scott DL, et al.
Published: (2011) -
Long-term treatment of rheumatoid arthritis with adalimumab
by: Murdaca G, et al.
Published: (2013) -
New and emerging therapies for the treatment of rheumatoid arthritis
by: Michael G Feely
Published: (2010)